Literature DB >> 2959304

A method for estimating the potency of angiotensin-converting enzyme inhibitors in man.

A Wellstein1, J Essig, G G Belz.   

Abstract

Dose-response curves of the effect of angiotensin I (A-I) infusion on diastolic blood pressure were constructed before and 3 h following single oral doses of the angiotensin-converting enzyme (ACE) inhibitor cilazapril (1.25 to 30 mg) in six normal male subjects. Cilazapril shifted the A-I dose-response curves dose dependently rightward; Schild-plot analysis indicated a competitive antagonism by cilazapril with an apparent Ki-dose of about 0.6 mg.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2959304      PMCID： PMC1386265          DOI： 10.1111/j.1365-2125.1987.tb03188.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  10 in total

1.  Theories of drug antagonism.

Authors:  J H GADDUM
Journal:  Pharmacol Rev       Date:  1957-06       Impact factor: 25.468

2.  A modification of receptor theory.

Authors:  R P STEPHENSON
Journal:  Br J Pharmacol Chemother       Date:  1956-12

3.  [Cilazapril in essential hypertension. A placebo-controlled double-blind study to establish the dosage].

Authors:  G G Belz; H Lange; W Tschollar; W Neis
Journal:  Med Klin (Munich)       Date:  1986-07-18

4.  The design of a new group of angiotensin-converting enzyme inhibitors.

Authors:  C H Hassall; A Kröhn; C J Moody; W A Thomas
Journal:  FEBS Lett       Date:  1982-10-18       Impact factor: 4.124

Review 5.  Enzymes of the renin-angiotensin system and their inhibitors.

Authors:  M A Ondetti; D W Cushman
Journal:  Annu Rev Biochem       Date:  1982       Impact factor: 23.643

6.  Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.

Authors:  A Wellstein; D Palm; H F Pitschner; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Characterization of angiotensin converting enzyme by [3H]captopril binding.

Authors:  S M Strittmatter; S H Snyder
Journal:  Mol Pharmacol       Date:  1986-02       Impact factor: 4.436

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.

Authors:  I L Natoff; J S Nixon; R J Francis; L R Klevans; M Brewster; J Budd; A T Patel; J Wenger; E Worth
Journal:  J Cardiovasc Pharmacol       Date:  1985 May-Jun       Impact factor: 3.105

10.  Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril.

Authors:  G G Belz; J Essig; A Wellstein
Journal:  J Cardiovasc Pharmacol       Date:  1987-02       Impact factor: 3.105
  10 in total
  10 in total

1.  Apparent racial difference in response to angiotensin I infusion.

Authors:  P H Joubert; H D Brandt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol.

Authors:  K A Erb; J Essig; K Breithaupt; G G Belz
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

Authors:  F Deget; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 4.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

5.  The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.

Authors:  J Essig; G G Belz; A Wellstein
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 6.  Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology.

Authors:  Gustav G Belz
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

7.  Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients.

Authors:  C H Kleinbloesem; K Erb; J Essig; K Breithaupt; G G Belz
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients.

Authors:  G G Belz; J Essig; K Erb; K Breithaupt; J F Hoogkamer; J Kneer; C H Kleinbloesem
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

9.  Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.

Authors:  C Malerczyk; B Fuchs; G G Belz; S Roll; R Butzer; K Breithaupt-Grögler; V Herrmann; S G Magin; A Högemann; B Voith; E Mutschler
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

10.  Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex.

Authors:  G G Belz; J Essig; C H Kleinbloesem; J F Hoogkamer; U W Wiegand; A Wellstein
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.